Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H27NO2 |
| Molecular Weight | 313.4339 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CCCC[C@@]35O)C2=C1
InChI
InChIKey=STBZIDOIKQNFCQ-HSALFYBXSA-N
InChI=1S/C20H27NO2/c22-16-6-5-15-11-18-20(23)8-2-1-7-19(20,17(15)12-16)9-10-21(18)13-14-3-4-14/h5-6,12,14,18,22-23H,1-4,7-11,13H2/t18-,19+,20-/m1/s1
| Molecular Formula | C20H27NO2 |
| Molecular Weight | 313.4339 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Oxilorphan (also known as levo-BC-2605) was developed as a long-acting, narcotic antagonist that has agonist properties. Oxilorphan is a partial agonist at the kappa-opioid receptor and antagonist of the mu-opioid receptor. During clinical trials, oxilorphan had led to dysphoria, which combined with its hallucinogenic effects, serves to limit its clinical usefulness. As a result, many patients who experienced these side effects refused to take additional doses in clinical trials.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:20 GMT 2025
by
admin
on
Mon Mar 31 17:51:20 GMT 2025
|
| Record UNII |
9Y9J2J74TO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3560
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
5361090
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106993
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
Oxilorphan
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
42281-59-4
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
100000083044
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
9Y9J2J74TO
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
255-749-8
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
C174594
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
C008732
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
SUB09530MIG
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY | |||
|
DTXSID001009897
Created by
admin on Mon Mar 31 17:51:20 GMT 2025 , Edited by admin on Mon Mar 31 17:51:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
